This is a preview of subscription content, log in via an institution to check access.
Notes
The study was supported by Pfizer Inc.
Reference
Sicras-Mainar A, et al. Cost comparison of adding pregabalin or gabapentin for the first time to the therapy of patients with painful axial radiculopathy treated in the community in Spain. Clinical and Experimental Rheumatology : 25 Feb 2013. Available from: URL: http://dx.doi.org/6251
Rights and permissions
About this article
Cite this article
Pregabalin less costly in axial radiculopathy in Spain. PharmacoEcon Outcomes News 674, 8 (2013). https://doi.org/10.1007/s40274-013-0249-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0249-1